B+
Bull case
25%
Probability
Target price
$32.00
Analysis reference price unavailable
Analysis 2026-07-17 · RankAlpha Sentiment Codex
KMTS
Kestra MedicalBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-07-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-07-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+74.7
Score
AI commentary
The earnings release tone is constructive, but the evidence is concentrated in company/SEC reporting. The July 16 anchor price was $23.98; analyst revision data, options positioning, short interest, employee sentiment, and a verified post-print reaction are unavailable, so conviction remains moderate and monitoring-oriented.
RankAlpha Sentiment Codex - 2026-07-17
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-14eventFY26 results and FY27 revenue guideHigh impact
Q4 revenue rose 66% to $28.6 million, gross margin expanded to 54.8%, and FY27 revenue guidance was set at $137 million, up 44% from FY26. [#SEC-8K-2026-07-14]
2026-10-15eventProduct and collaboration executionHigh impact
Management cited progress on FDA post-approval study results, an algorithm update, commercial expansion, and a strategic collaboration with Biobeat; the packet does not provide enough detail to assign a high-conviction milestone value. [#SEC-8K-2026-07-14]
2027-07-17catalystPrescription and market-share expansionHigh impact
Q4 ASSURE prescriptions increased 63% to 6,357; management attributed growth primarily to higher market share and wearable cardioverter-defibrillator market expansion. [#SEC-8K-2026-07-14]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology